Scotiabank analyst Greg Harrison raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $486 from $480 and keeps a Sector Perform rating on the shares. The company posted a beat and raise for Q3, with total revenues coming above consensus, the analyst tells investors. The firm sees “a lot to like” with the company’s story, given the strong commercial execution and approval of Vanza triple in cystic fibrosis and suzetrigine in acute paint expected January.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $560 from $502 at Bernstein
- Vertex Pharmaceuticals price target raised to $476 from $473 at Morgan Stanley
- Vertex Pharmaceuticals Reports Strong Q3 2024 Growth
- VRTX Earnings: Vertex Pharmaceutical’s Financial Results Beat Wall Street Targets
- Closing Bell Movers: Palantir jumps 13% after results